1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
Sinopharm Group Co. Ltd.

Sinopharm Group Co. Ltd.

SHTDY
Sinopharm Group Co. Ltd.US flagOther OTC
10.73
USD
+0.01
- -
6.70BMarket Cap
Sinopharm Group Co. Ltd.
SHTDY
(Other OTC)

Recent

price

10.73

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
152.86
216.94
284.07
330.64
387.07
413.13
467.63
518.77
580.47
715.55
733.51
837.39
884.67
955.84
936.51
921.55
234.79
Revenue per Share
2.67
3.31
4.12
4.46
5.56
6.82
8.42
9.4
9.83
10.52
11.55
12.47
13.66
14.51
11.3
11.46
3.23
Basic EPS, GAAP
-0.58
-0.23
4.86
7.21
7.1
21.89
14.3
1.58
0.42
27.31
14.57
11.33
29.72
23.77
15.35
20.06
-2.09
Free Cash Flow per Basic Share
0.05
0.87
0.95
1.27
1.29
1.55
2.06
2.33
2.66
2.95
3
3.46
3.75
4.1
4.35
3.4
- -
Dividend per Share
5
5.1
5
15.61
5.35
23.13
29.36
4.67
5.01
5
5.02
5.02
73.76
84.17
91.11
99.18
86.68
Book Value per Share
27.52
33.41
36.21
45.59
57.91
61.72
69.3
85.48
102.4
111.29
124.37
140.55
157.09
173.48
185.41
198.7
181.89
Tangible Book Value per Share
453
471
481
505
517
553
552
593
594
594
622
622
624
624
624
624
617
Basic Weighted Avg Shares
69,234
102,225
136,502
166,866
200,131
228,633
258,117
307,666
344,526
425,273
456,415
521,051
552,148
596,570
584,508
575,168
144,969
Sales/Revenue/Turnover
3.48
3.56
3.57
3.66
3.93
4.02
3.85
4.05
4.57
4.35
4.33
4.03
4.08
3.73
3.04
2.97
3.46
Operating Margin (%)
301
460
567
677
835
1,006
1,068
1,240
1,395
3,114
3,597
3,922
4,165
4,430
4,734
4,289
- -
Depreciation Expense
1,209
1,561
1,979
2,250
2,875
3,772
4,647
5,576
5,836
6,253
7,187
7,759
8,526
9,054
7,050
7,155
1,992
Net Income, GAAP
23.67
23.18
23.28
22.53
23.3
23.14
22.78
22.82
22.96
22.82
22.44
23.16
22.72
23.07
25.55
26.79
23.72
Effective Tax Rate (%)
1.75
1.53
1.45
1.35
1.44
1.65
1.8
1.81
1.69
1.47
1.57
1.49
1.54
1.52
1.21
1.24
1.37
Profit Margin (%)
9,109
15,942
16,111
18,872
24,253
22,278
33,022
38,188
44,580
51,575
63,633
71,616
84,443
95,344
97,072
100,070
99,125
Working Capital
91
5,182
5,192
4,134
4,223
608
11,135
5,594
5,019
11,470
12,162
11,669
14,957
17,255
11,897
6,141
19,606
LT Debt
14,719
20,388
22,949
28,611
36,290
40,879
44,532
57,947
68,276
76,939
89,947
99,654
110,069
120,319
126,687
134,160
122,433
Total Equity
10.74
10.51
10.03
10.04
9.96
10.35
10.29
10.91
10.92
10.99
10.39
9.72
9.84
9.02
6.57
6.05
- -
Return on Invested Capital (%)
11.49
9.23
8.34
7.06
7.11
7.28
6.93
7.61
6.47
5.31
5.12
4.98
4.07
3.26
3.23
2.83
4.45
Return on Capital (%)
53.38
66.88
82.38
43.76
54
48.46
32.04
58.78
203.38
210.41
235.95
248.62
34.69
18.37
12.89
12.05
470.76
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
ST Debt
- -
81,450
LT Borrowings
- -
15,925
LT Finance Leases
- -
3,680
Preferred Equity and Hybrid Capital
- -
- -
Shares Outstanding
- -
3,121
Market Capitalization
57,094
59,115

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Total Current Assets
- -
382,363
Cash, Cash Equivalents & STI
- -
43,332
Accounts Receivable, Net
- -
234,307
Inventories
- -
68,838
Total Current Liabilities
- -
283,238
Payables & Accruals
- -
- -
ST Debt
- -
81,450
Deferred Revenue
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.82%
8.35%
5.9%
Free Cash Flow
627.68%
23.21%
30.73%
Net Income, GAAP
7.33%
0.68%
1.5%
Sales/Revenue/Turnover
9.94%
4.91%
-1.6%
Total Cash Common Dividend
10.35%
3.55%
-21.84%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
144,969
- -
- -
596,570
2024
- -
- -
- -
- -
584,508
2025
- -
- -
- -
- -
575,168

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
14.51
2024
- -
- -
- -
- -
11.3
2025
- -
- -
- -
- -
11.46

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
4.1
2024
- -
- -
- -
- -
4.35
2025
- -
- -
- -
- -
3.4
Similar Companies
Cencora, Inc. (COR)
Ame Company For Medical Supplies (9527.SR)
Yooma Wellness Inc (LVVEF)
ShareHope Medicine Co., Ltd. (8403.TWO)
Checkpoint Trends Limited (CHECKPOINT.BO)
Exlites Holdings International, Inc. (EXHI)
Business
Sinopharm Group Co. Ltd. (SHTDY) operates as China's largest distributor of pharmaceutical and healthcare products and a leading supply chain services provider, with integrated operations across pharmaceutical distribution, medical devices distribution, retail pharmacy, and other businesses including pharmaceutical manufacturing, chemical reagents, and laboratory supplies. The company distributes pharmaceuticals, antibiotics, biological products, Chinese herbal medicines, and medical devices such as diagnostic equipment, surgical instruments, and patient monitoring systems; it provides logistics, value-added services, installation, maintenance, retail chain operations, and franchising for over 10,000 pharmacies including community, direct-to-patient, and dual-channel outlets serving therapeutic areas like oncology, cardiology, infectious diseases, chronic disease management, and wellness products; additionally, it manufactures and sells pharmaceutical products while offering information technology, investment, import-export, consulting, health, and exhibition services. Founded in 2003 and headquartered in Shanghai, China, Sinopharm Group primarily serves the domestic market through a network of approximately 600,000 outlets nationwide and maintains over 1,100 subsidiaries including listed entities China National Medicines Co. Ltd. (600511.SH) and China National Accord Medicines Co. Ltd. (000028.SZ), operating as a subsidiary of China National Pharmaceutical Group Co. Ltd. with around 120,000 employees. Recent developments include the extension of its Suzhou Capsugel joint venture with Lonza for 20 years in May 2025 to bolster capsule manufacturing capabilities; expansion of business collaborations and attendance at the seventh China International Import Expo in November 2024; renewal of distribution agreements such as with Shanghai Henlius Biotech; strategic meetings with global executives from Fresenius Kabi and RX in April 2025 to enhance partnerships; and the appointment of a new president, Mr. Wanyong Lian, in August 2024 alongside institutional investor stake increases by JPMorgan Chase and BlackRock in late 2025.

Company News

APIChatGPT

  • accessnewswire.com

    Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities

  • prnewswire.com

    Lakeside Signs $1.5 Million Sales Agreement with Sinopharm Group Subsidiary

  • prnewswire.com

    Lakeside Strengthens Market Position in China's Pharmaceutical Logistics with Key Sinopharm(Hubei) Contracts

  • seekingalpha.com

    Pandemic Accelerates China's Drive Into mRNA Treatments

  • seekingalpha.com

    Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines

  • seekingalpha.com

    Diversifying Into Top-Ranked Sinopharm

  • seekingalpha.com

    Week In Review: Sinopharm Transfers $4.6 Billion In Assets Including Two COVID-19 Vaccines

  • seekingalpha.com

    Week In Review: Eluminex Raises $50 Million For Ophthalmology Drugs